Neumora Therapeutics (NASDAQ:NMRA) Insider Daljit Singh Aurora Sells 34,987 Shares

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Daljit Singh Aurora sold 34,987 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $1.59, for a total transaction of $55,629.33. Following the completion of the sale, the insider directly owned 123,660 shares in the company, valued at $196,619.40. This represents a 22.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Daljit Singh Aurora also recently made the following trade(s):

• On Wednesday, August 19th, Daljit Singh Aurora sold 30,918 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total transaction of $51,014.70.
• On Wednesday, August 19th, Daljit Singh Aurora sold 31,000 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.65, for a total transaction of $51,150.00.
• On Monday, August 17th, Daljit Singh Aurora sold 55,016 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.50, for a total value of $82,524.00.
• On Monday, August 17th, Daljit Singh Aurora sold 91,690 shares of Neumora Therapeutics stock. The shares were sold at an average price of $1.50, for a total value of $137,535.00.
• On Tuesday, August 18th, Daljit Singh Aurora sold 34,162 shares of Neumora Therapeutics stock. The stock was sold at an average price of $1.58, for a total transaction of $53,975.96.

Neumora Therapeutics Stock Performance

Shares of NASDAQ:NMRA remained flat at $1.64 on Wednesday. The stock had a trading volume of 716,090 shares, compared to its average volume of 699,708. The company’s 50 day moving average price is $1.61 and its 200-day moving average price is $2.11. Neumora Therapeutics, Inc. has a 12 month low of $0.83 and a 12 month high of $3.65. The company has a debt-to-equity ratio of 1.19, a quick ratio of 5.09 and a current ratio of 4.50.

Neumora Therapeutics (NASDAQ:NMRA) last announced its earnings results on Friday, August 14th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. Equities analysts predict that Neumora Therapeutics, Inc. will post -0.85 earnings per share for the current year.

Institutional Trading of Neumora Therapeutics

A number of institutional investors have recently added to or reduced their stakes in NMRA. Johnson & Johnson bought a new stake in shares of Neumora Therapeutics during the 2nd quarter worth about $3,144,057,000. Perceptive Advisors LLC acquired a new stake in Neumora Therapeutics in the 1st quarter worth approximately $9,953,000. Siren L.L.C. boosted its position in Neumora Therapeutics by 35.1% during the first quarter. Siren L.L.C. now owns 8,497,822 shares of the company’s stock worth $16,571,000 after purchasing an additional 2,209,039 shares during the period. GSA Capital Partners LLP boosted its position in Neumora Therapeutics by 392.6% during the fourth quarter. GSA Capital Partners LLP now owns 534,044 shares of the company’s stock worth $956,000 after purchasing an additional 425,633 shares during the period. Finally, ICONIQ Capital LLC acquired a new position in Neumora Therapeutics during the second quarter valued at approximately $4,350,000. 47.65% of the stock is currently owned by institutional investors and hedge funds.

More Neumora Therapeutics News

Here are the key news stories impacting Neumora Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.89 from $1.29 and its FY2027 forecast to a loss of $0.68 from $1.25, indicating analysts expect substantially narrower losses over the next two years.
• Positive Sentiment: The firm also improved its quarterly outlook, forecasting a Q3 2026 loss of $0.20 per share versus $0.32 previously and a Q4 2026 loss of $0.16 versus $0.30 previously.
• Positive Sentiment: Longer-term estimates were upgraded sharply: FY2028’s projected loss narrowed to $0.52 from $1.10, FY2029 moved to projected profit of $0.20 from a $0.26 loss, and FY2030 profit expectations increased to $1.83 from $1.51 per share. These changes imply a faster potential transition to profitability.
• Positive Sentiment: HC Wainwright’s current estimates call for losses of $0.15, $0.16, $0.19 and $0.17 per share in the first four quarters of 2027, respectively, with full-year 2027 losses of $0.68. The firm’s continued Buy rating provides additional support for investor sentiment.
• Neutral Sentiment: Neumora remains unprofitable, with the broader current-year consensus at a loss of $0.93 per share. The company’s shares are trading well below their 200-day moving average and remain near the lower portion of their 12-month range, underscoring continued execution and financing risks despite the improved forecasts.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on NMRA shares. Royal Bank Of Canada decreased their target price on Neumora Therapeutics from $7.00 to $5.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Weiss Ratings lowered shares of Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. HC Wainwright restated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday, July 28th. Wall Street Zen raised shares of Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, Needham & Company LLC dropped their price objective on shares of Neumora Therapeutics from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, June 16th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.57.

About Neumora Therapeutics

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.